[india-drug] RFI: Coronary-Stent eluting drugs-A more cautious view(3)

["Dr Krisantha Weerasuriya" <weerasuriyak@whosea.org>]

The Lancet (14 August) had a meta-analysis on drug-eluting stents.

http://www.thelancet.com/journal/vol364/iss9434/full/llan.364.9434.primary_resea
rch.30460.1

The Interpretation that was in the Summary is given below

Quote
Interpretation Sirolimus-eluting and polymeric paclitaxel-eluting stents are
effective at decreasing rates of angiographic restenosis and major adverse
cardiac events compared with BMS. However, there is no evidence that they affect mortality or myocardial-infarction rates. They also appear to be safe in the short to medium term, although definitive conclusions are not possible. Larger studies with longer follow-up are needed to define better the role of these new devices.
Unquote

The comment on the meta-analysis has free access

http://www.thelancet.com/journal/vol364/iss9434/full/llan.364.9434.talking_point
s.30511.1

So, although promising, the full story is yet to be told.

So those of us male middle-aged and senior India E-druggers who follow this area with keen professional (and personal?!) interest, you will have to keep an eye out for the future reports.

DrKW

Dr Krisantha Weerasuriya
Essential Drugs and Medicines Policy (EDM)
WHO South-East Asia Regional Office (SEARO),
World Health House, New Delhi, 110 002, India
Phone +91 11 2337 0804  ext 26314
Mobile +91 98104 16366
Fax +91 11 2337 8510
Email: weerasuriyak@whosea.org